everolimus / Generic mfg. |
NCT01115803: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors |
|
|
| Terminated | 1b | 29 | US, Europe | LY2584702, Erlotinib, Everolimus | Eli Lilly and Company | Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors | 06/11 | 06/11 | | |
NCT01677390: A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma |
|
|
| Terminated | 1b | 4 | US | SGN-75, everolimus | Seagen Inc. | Renal Cell Carcinoma | 12/13 | 12/13 | | |
NCT01508104: Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors |
|
|
| Terminated | 1b | 19 | US | BEZ235, Everolimus, RAD001 | University of Cincinnati, Novartis | Cancer | 02/14 | 12/14 | | |
NCT02106507: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate |
|
|
| Completed | 1b | 9 | US | apalutamide, Everolimus | Memorial Sloan Kettering Cancer Center, Aragon Pharmaceuticals, Inc. | Prostate Cancer | 06/21 | 06/21 | | |
|
ACTRN12612000136808: Phase I study of RAD001 (Everolimus) in combination with Fluvastatin and Zoledronic acid in patients with solid tumours |
|
|
| Active, not recruiting | 1 | 25 | | | St George Hospital, Novartis Pharmaceuticals Australia Pty Ltd | Advanced cancers | | | | |
NCT00352443: S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Completed | 1 | 66 | US | everolimus, lapatinib ditosylate | Southwest Oncology Group, National Cancer Institute (NCI) | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | 08/07 | 09/13 | | |
|
NCT00613132: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG |
|
|
| Completed | 1 | 78 | US | Gleevec, RAD001, and Hydroxyurea, Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide | Annick Desjardins, Novartis Pharmaceuticals | Glioblastoma, Gliosarcoma | 08/08 | 01/13 | | |
NCT00187174: Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors |
|
|
| Completed | 1 | 41 | US | Everolimus | St. Jude Children's Research Hospital, Novartis | Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue | 10/08 | 10/08 | | |
NCT00680758: Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer |
|
|
| Completed | 1 | 18 | US | cisplatin, Platinol, everolimus, RAD001, paclitaxel, Taxol | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 08/09 | 12/10 | | |
NCT00478634: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 19 | US | RAD001, Cetuximab, Irinotecan | Novartis Pharmaceuticals | Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal | 09/09 | 09/09 | | |
NCT00655655: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 96 | US | everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, vatalanib, CGP-79787, PTK787/ZK 222584, pharmacological study, pharmacological studies, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, DCE-MRI, ultrasound imaging, ultrasonography, ultrasound, ultrasound test | Mayo Clinic, National Cancer Institute (NCI) | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific | 09/09 | 01/18 | | |
NCT00373815: Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease |
|
|
| Terminated | 1 | 10 | Europe | Everolimus | University Hospital Tuebingen | Graft Versus Host Disease | | 10/09 | | |
NCT00457119: Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients |
|
|
| Completed | 1 | 69 | US, Europe, RoW | RAD001, Everolimus | Novartis Pharmaceuticals | Non Small Cell Lung Cancer | 11/09 | 11/09 | | |
|
NCT00729638: RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma |
|
|
| Completed | 1 | 28 | US | RAD001, lenalidomide | Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin | Multiple Myeloma | 11/09 | 11/09 | | |
NCT00422344: A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma |
|
|
| Completed | 1 | 20 | US | RAD001, Sunitinib | Memorial Sloan Kettering Cancer Center, Novartis | Renal Cell Carcinoma, Kidney Cancer | 02/10 | 02/10 | | |
NCT00544999: Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia |
|
|
| Unknown status | 1 | 21 | Europe | cytarabine, daunorubicin hydrochloride, everolimus, laboratory biomarker analysis, pharmacological study | Institut de Recherche Clinique sur les Cancers et le Sang | Leukemia | 04/10 | | | |
NCT00703807: Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers |
|
|
| Completed | 1 | 10 | US | Topotecan, Hycamtin, RAD001, Everolimus | Yale University, Novartis | Endometrial Cancer | 05/10 | 05/10 | | |
|
| Completed | 1 | 50 | Europe | everolimus (RAD001) | Novartis Pharmaceuticals | Breast Neoplasms, Neoplasm Metastasis | 06/10 | 06/10 | | |
NCT00303732: Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 37 | US | RAD001 (everolimus), Afinitor, PTK787 (vatalanib) | Daniel George, MD, Novartis | Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 08/10 | 08/12 | | |
NCT00807755: Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors |
|
|
| Terminated | 1 | 5 | US | Carboplatin, Paraplatin, Etoposide, Eposin, Etopophos, Vepesid, VP-16, RAD001, Everolimus, Afinitor | University of California, Davis, Novartis | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 08/10 | 12/11 | | |
NCT00387400: Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme |
|
|
| Completed | 1 | 32 | Canada | everolimus, temozolomide, microarray analysis, immunohistochemistry staining method | NCIC Clinical Trials Group | Brain and Central Nervous System Tumors | 09/10 | 01/12 | | |
NCT00466466: Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients |
|
|
| Completed | 1 | 20 | Europe, US | Everolimus, RAD001 | Novartis Pharmaceuticals | Small-Cell Lung Cancer | 11/10 | | | |
|
NCT00968591: Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency |
|
|
| Completed | 1 | 34 | Europe, RoW | Everolimus | Novartis Pharmaceuticals | Hepatic Insufficiency | 11/10 | | | |
NCT00434174: Safety of Everolimus and Pemetrexed in Lung Cancer Patients |
|
|
| Completed | 1 | 48 | Europe, RoW | Everolimus, RAD001, Affinitor, Pemetrexed | Novartis Pharmaceuticals | Non Small Cell Lung Cancer | 12/10 | 12/10 | | |
NCT00967928: Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer |
|
|
| Withdrawn | 1 | 0 | US | RAD001, Afinitor, Everolimus, Cisplatin, CDDP, Platinol, External Beam Whole Pelvis Radiation Therapy | Accelerated Community Oncology Research Network, Novartis Pharmaceuticals | Cervical Cancer | 12/10 | 12/10 | | |
NCT00927966: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms |
|
|
| Completed | 1 | 21 | US | RAD001, CP-751,871 | Suzanne George, MD, Brigham and Women's Hospital, Novartis, Pfizer | Sarcoma, Solid Tumor | 01/11 | 01/11 | | |
| Completed | 1 | 42 | US | Patupilone, RAD001 | University of Medicine and Dentistry of New Jersey, Novartis Pharmaceuticals, National Cancer Institute (NCI) | Refractory Malignancy | 02/11 | 02/11 | | |
NCT00456833 / 2004-003017-16: Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy |
|
|
| Completed | 1 | 248 | Europe, Canada, US, RoW | RAD001, erlotinib | Novartis Pharmaceuticals | Non Small Cell Lung Cancer | 03/11 | | | |
|
NCT01148628: Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors |
|
|
| Unknown status | 1 | 54 | Europe | RAD 001 in combination with Caelyx | Southern Europe New Drug Organization, Novartis, Schering-Plough | Advanced Solid Tumors | 03/11 | 12/11 | | |
NCT01057277: RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer |
|
|
| Terminated | 1 | 3 | US | RAD001(Afinitor), Afinitor | howard safran, Rhode Island Hospital, The Miriam Hospital, Memorial Hospital of Rhode Island, Roger Williams Medical Center | Head and Neck Cancer | 05/11 | 06/11 | | |
NCT01332279: Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy |
|
|
| Withdrawn | 1 | 0 | US | everolimus, RAD001, Afinitor, 42-O-(2-hydroxy)ethyl rapamycin, erlotinib hydrochloride, erlotinib, TARCEVA, OSI-774, biopsy, biopsies, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, polyacrylamide gel electrophoresis, electrophoresis, polyacrylamide gel, pharmacological study, pharmacological studies, external beam radiation therapy, EBRT, microarray analysis, gene expression profiling | Fox Chase Cancer Center | Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer | 05/11 | 05/11 | | |
|
NCT00828594 / 2008-004096-21: Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma |
|
|
| Terminated | 1 | 130 | US, Europe, RoW | RAD001, RAD001, sorafenib | Novartis Pharmaceuticals | Hepatocellular Carcinoma | 06/11 | 06/11 | | |
|
|
NCT01063478: Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC |
|
|
| Terminated | 1 | 3 | US | RAD001 (in addition to standard radiation and chemotherapy), RAD001 (Everolimus) | University of Chicago, Novartis Pharmaceuticals | Non-Small Cell Lung Cancer | 06/11 | 01/12 | | |
NCT01637194: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
|
|
| Completed | 1 | 12 | US | everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, pharmacological study, pharmacological studies, laboratory biomarker analysis | Fox Chase Cancer Center, National Cancer Institute (NCI) | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Colon Cancer, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Colon Cancer, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Tongue Cancer | 07/11 | 07/11 | | |
NCT01049620: RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX |
|
|
| Completed | 1 | 40 | RoW | RAD001, Capecitabine, Oxaliplatin | Asan Medical Center | Advanced Gastric Cancer | 07/11 | 09/13 | | |
|
BEL, NCT01055795: Safety Study of Bevacizumab, Everolimus and LBH589 () for Advanced Solid Tumors |
|
|
| Completed | 1 | 14 | US | Bevacizumab, Everolimus and LBH589 | Herbert Hurwitz, Novartis, Genentech, Inc. | Advanced Solid Tumors | 08/11 | 05/12 | | |
|
NCT00423865: Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 30 | US | cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 09/11 | 09/11 | | |
NCT00955773: A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects |
|
|
| Completed | 1 | 64 | US, Europe | GSK1120212 plus everolimus | GlaxoSmithKline | Cancer | 11/11 | 11/11 | | |
|
|
|
NCT00473005: Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast |
|
|
| Terminated | 1 | 18 | US | Capecitabine, Xeloda, Roche, RAD001, Everolimus, Zortress, Certican, Afinitor | Stanford University, Novartis | Breast Cancer | 12/11 | 12/11 | | |
NCT01058408: RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer |
|
|
| Terminated | 1 | 3 | US | Intensity modulated radiotherapy, IMRT, RAD001, cisplatin | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Novartis | Head and Neck Cancer | 02/12 | | | |
NCT00253318: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer |
|
|
| Terminated | 1 | 15 | US | Docetaxel, Taxotere, RAD001, Dexamethasone, Decadron | M.D. Anderson Cancer Center, Novartis Pharmaceuticals | Breast Cancer | 04/12 | 04/12 | | |
ACTRN12610000405011: This study is examining the safety and tolerability of a new drug (Everolimus) in combination with chemotherapy in the treatment of relapsed adult acute lymphobastic leukaemia |
|
|
| Terminated | 1 | 20 | | | Australasian Leukaemia and Lymphoma Group, Novartis Pharmaceuticals Australia Pty Ltd | acute lymphobastic leukaemia (ALL) | | | | |
NCT01079481: Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer |
|
|
| Completed | 1 | 21 | RoW | taxol plus everolimus | Samsung Medical Center | Small Cell Lung Cancer | 05/12 | 04/13 | | |
|
S387, NCT01042782: Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction |
|
|
| Completed | 1 | 16 | Europe | RAD001 and MitomycinC, RAD001 (everolimus) | Krankenhaus Nordwest | Advanced Gastric Cancer, Advanced Cancer of the Esophagogastric Junction | 08/12 | 08/12 | | |
|
NCT01096199: A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus) |
|
|
| Terminated | 1 | 35 | RoW | TS-ONE, Cisplatin, RAD001 | National University Hospital, Singapore | Cancer | 09/12 | | | |
NCT00276575: Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 65 | US | bevacizumab, erlotinib hydrochloride, everolimus | Herbert Hurwitz, MD, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 10/12 | 09/14 | | |
NCT01714765: Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer |
|
|
| Completed | 1 | 17 | Europe | Dovitinib, Everolimus | Queen Mary University of London, Novartis | Metastatic Clear Cell Renal Cancer | 10/12 | 10/12 | | |
|
|
|
NCT01074086: Phase I Study in RAD 001 Patients With Relapse AML |
|
|
| Completed | 1 | 31 | Europe | RAD 001, everolimus | French Innovative Leukemia Organisation, Novartis Pharmaceuticals | AML | 12/12 | 12/12 | | |
|
|
| Completed | 1 | 5 | US | Everolimus (RAD001), RAD001, Sunitinib (Sutent), Sutent | Daniel George, MD, Novartis, Pfizer | Renal Cell Carcinoma | 12/12 | 12/12 | | |
NCT00943956: Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer |
|
|
| Completed | 1 | 30 | Europe | bicalutamide, everolimus, leuprolide acetate, external beam radiation therapy | Institut du Cancer de Montpellier - Val d'Aurelle | Prostate Cancer | 12/12 | 12/12 | | |
|
COBRA, NCT00849550: Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. |
|
|
| Completed | 1 | 32 | US | capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Herbert Hurwitz, Roche-Genentech, Novartis | Unspecified Adult Solid Tumor, Protocol Specific, Cancer | 12/12 | 12/12 | | |
|
NCT00962507: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma |
|
|
| Completed | 1 | 11 | US | everolimus, panobinostat, laboratory biomarker analysis, pharmacological study | City of Hope Medical Center, National Cancer Institute (NCI) | Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm | 01/13 | 01/13 | | |
NCT00942682: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
|
|
| Completed | 1 | 21 | US | Sorafenib, RAD001 | Dana-Farber Cancer Institute, Novartis, Bayer | Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor | 03/13 | 03/13 | | |
|
NCT00610948: Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment |
|
|
| Completed | 1 | 74 | US | panitumumab, Vectibix, everolimus, Afinitor, fluorouracil, 5FU, leucovorin calcium, oxaliplatin, Eloxatin | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 05/13 | 01/16 | | |
NCT01154335: Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 18 | US | OSI-906, Everolimus | SCRI Development Innovations, LLC, Novartis Pharmaceuticals, OSI Pharmaceuticals | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
AML1208, NCT01154439: Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Completed | 1 | 11 | Europe | cytarabine, Mini-ICE regimen (idarubicin, cytarabine and etoposide)., etoposide, everolimus, RAD001, idarubicin, mitoxantrone hydrochloride | Gruppo Italiano Malattie EMatologiche dell'Adulto | Leukemia | 05/13 | 09/15 | | |
EVAX, NCT01334073: Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors |
|
|
| Completed | 1 | 19 | Europe | Axitinib plus everolimus | University Hospital, Bordeaux | Malignant Advanced Solid Tumors, Carcinoma, Renal Cell | 05/13 | 01/15 | | |
| Unknown status | 1 | 60 | Europe | Everolimus and sorafenib | Hospices Civils de Lyon | Metastatic or Locally Advanced Solid Tumors | 05/13 | 10/15 | | |
|
NCT00985374 / 2008-005806-38: A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 11 | US, Europe | RAD001, RG1507 | Hoffmann-La Roche | Neoplasms | 06/13 | 06/13 | | |
NCT00858663: Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer |
|
|
| Completed | 1 | 13 | US | intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals | Head and Neck Cancer | 07/13 | 07/13 | | |
NCT00636922: Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia |
|
|
| Unknown status | 1 | 40 | RoW | RAD001(Everolimus), Everolimus | Bayside Health | Acute Myeloid Leukemia | 07/13 | 01/14 | | |
NCT00935961: RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer |
|
|
| Completed | 1 | 18 | US | RAD001 + docetaxel + cisplatin | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals | HEAD & NECK Cancer | 08/13 | 08/13 | | |
|
| Completed | 1 | 21 | US | RAD001 and Sorafenib | University of California, San Francisco, Novartis | Renal Cell Carcinoma | 12/13 | 03/14 | | |
NCT00401778: Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 1 | 33 | US | RAD001, Everolimus | Emory University | Lung Cancer | 12/13 | 12/13 | | |
NCT01152801: Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer |
|
|
| Completed | 1 | 64 | RoW | Everolimus (RAD001) | Novartis Pharmaceuticals | Metastatic Renal Cell Carcinoma | 12/13 | 12/13 | | |
|
NCT00622258: A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Completed | 1 | 13 | Japan | Everolmus, RAD001 | Novartis Pharmaceuticals | Non-Hodgkin's Lymphoma | 01/14 | 01/14 | | |
| Completed | 1 | 36 | Europe | Combination of sorafenib and everolimus, Nexavar, RAD001 | University of Cologne | Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer | 02/14 | 02/15 | | |
|
|
|
|
NCT00426556 / 2006-001596-37: Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer |
|
|
| Completed | 1 | 88 | US, Europe | Everolimus, RAD001, Trastuzumab, Paclitaxel | Novartis Pharmaceuticals | Metastatic Breast Cancer | 03/14 | 03/14 | | |
|
COOPERATE-1, NCT01263353: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs |
|
|
| Completed | 1 | 36 | Europe | Pasireotide LAR followed by Pasireotide LAR + Everolimus, Everolimus followed by Pasireotide LAR + Everolimus | Novartis Pharmaceuticals | Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System | 03/14 | 03/14 | | |
PHOENIX I, NCT01217177: A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer |
|
|
| Completed | 1 | 14 | RoW | everolimus, RAD001 | Novartis Pharmaceuticals | Locally Advanced Cervical Cancer | 04/14 | 04/14 | | |
NCT01324492: Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor |
|
|
| Completed | 1 | 16 | RoW | RAD001, Everolimus | Novartis Pharmaceuticals | Lung Neuroendocrine Neoplasm | 06/14 | 06/14 | | |
RAD001, NCT01167530: Study to Evaluate in Combination With Radiotherapy in Non-small Cell Lung Cancer |
|
|
| Unknown status | 1 | 36 | Europe | Everolimus | Gustave Roussy, Cancer Campus, Grand Paris, Novartis | Non-small Cell Lung Cancer, Locally Advanced Disease | 07/14 | 07/14 | | |
|
NCT00949949: Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy |
|
|
| Completed | 1 | 38 | US | everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, cisplatin, CACP, CDDP, CPDD, DDP | Mayo Clinic, National Cancer Institute (NCI) | Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 07/14 | 07/14 | | |
NCT01204476: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
|
|
| Completed | 1 | 27 | US | Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Pharmacological Study | National Cancer Institute (NCI) | Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma | 07/14 | | | |
|
|
NCT01642732: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer |
|
|
| Terminated | 1 | 1 | US | Everolimus, lupron, bicalutamide, and radiation, afinitor, RAD-001, Casodex, Leuprolide, Eligard | University of Michigan Rogel Cancer Center, Novartis Pharmaceuticals | Prostate Cancer | 08/14 | 08/14 | | |
| Completed | 1 | 56 | US | bevacizumab, everolimus, panitumumab, avastin, RAD001 | Herbert Hurwitz, MD, Novartis, Genentech, Inc., Amgen | Solid Tumors | 09/14 | 09/14 | | |
|
NCT00804336: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
|
|
| Completed | 1 | 22 | US | SOM230, pasireotide, RAD001 | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis | Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor | 09/14 | 04/15 | | |
| Completed | 1 | 18 | Europe | Everolimus + BIBF 1120, Everolimus, RAD001, Afinitor, BIBF 1120 | University of Cologne, Boehringer Ingelheim | Solid Tumors | 10/14 | 05/16 | | |
|
NCT01700400: Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer |
|
|
| Completed | 1 | 13 | US | Everolimus, Afinitor, Zortress, RAD001, Pemetrexed, Alimta, Carboplatin, Paraplatin, CBDCA, Bevacizumab, Avastin | Cancer Research and Biostatistics Clinical Trials Consortium, University of Arizona, Providence Cancer Center, Earle A. Chiles Research Institute, Novartis Pharmaceuticals | Non Small Cell Lung Cancer | 10/14 | 10/14 | | |
NCT01122199: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 27 | US | RAD001 + AMG479, everolimus + ganitumab | Shadia Jalal, Amgen, Novartis | Neoplasm Metastases | 01/15 | 01/15 | | |
|
|
|
NCT01482156: Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 46 | Europe, US, RoW | RAD001 + BEZ235, Afinitor | Novartis Pharmaceuticals | Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma | 02/15 | 02/15 | | |
NCT01334502: Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma |
|
|
| Completed | 1 | 26 | US | rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Lymphoma | 02/15 | 08/17 | | |
|
|
NCT01088048: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia |
|
|
| Completed | 1 | 241 | US | Idelalisib, GS-1101, CAL-101, Zydelig®, Rituximab, Rituxan, Bendamustine, Treanda, Ofatumumab, Arzerra, Fludarabine, Fludara, Everolimus, Afinitor, RAD-001, Bortezomib, Velcade, codenamed PS-341, Chlorambucil, Leukeran, Lenalidomide, Revlimid | Gilead Sciences | Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 04/15 | 04/15 | | |
|
|
|
|
|
|
|
|
|
|
|
ChiCTR-IPC-14005473: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study |
|
|
| Not yet recruiting | 1 | 24 | | RT(1.5MG) ;TR(1.5mg each period) | the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution:, Shandong Xinshidai Pharmaceutical Co., Ltd. | Healthy Volunteers | | | | |
ChiCTR-IPR-14005691: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study |
|
|
| Not yet recruiting | 1 | 24 | | RT(1.5MG) ;TR(1.5mg each period) | the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution:, Shandong Xinshidai Pharmaceutical Co., Ltd. | Healthy Volunteers | | | | |
NCT00756340: A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors |
|
|
| Completed | 1 | 16 | US | Bevacizumab, Avastin(R), Everolimus, RAD001, Afinitor(R) | St. Jude Children's Research Hospital, Novartis Pharmaceuticals | Recurrent or Refractory Solid Tumors, CNS Malignancies | 09/15 | 09/15 | | |
NCT00671112: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma |
|
|
| Terminated | 1 | 30 | US | Bortezomib, Velcade, Everolimus, RAD001 | Brian Hill, MD, PhD, National Cancer Institute (NCI), The Leukemia and Lymphoma Society | 714leukemia, Lymphoma | 10/15 | | | |
NCT02616848: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers |
|
|
| Unknown status | 1 | 1 | Europe | Everolimus, Eribulin | Istituti Ospitalieri di Cremona | Triple Negative Breast Cancer | 11/15 | | | |
NCT01733004: A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 42 | US, Europe | MM-141 | Merrimack Pharmaceuticals | Hepatocellular Carcinoma | 01/16 | | | |
|
|
|
NCT01182168: Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies |
|
|
| Completed | 1 | 12 | US | gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals | Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer | 03/16 | 03/16 | | |
|
2012-000299-40: A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects |
|
|
| | 1 | 40 | US | Everolimus, RAD001, Tablet | Novartis Pharma Services AG, Novartis Pharma Services AG | Healthy volunteers, Not applicable, Diseases [C] - Cancer [C04] | | | | |
NCT01341834: Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors |
|
|
| Unknown status | 1 | 49 | RoW | LBH589 and RAD001 | National Cancer Centre, Singapore, Novartis | Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour | 06/16 | 12/18 | | |
|
|
| Completed | 1 | 31 | Europe, US, RoW | AEB071, sotrastuarin, Everolimus, RAD001 | Novartis Pharmaceuticals | CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma | 06/16 | 06/16 | | |
| Completed | 1 | 164 | Europe, RoW | Everolimus, Exemestane, BI 836845, xentuzumab | Boehringer Ingelheim | Neoplasms | 11/16 | 12/21 | | |
|
NCT01523977: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL |
|
|
| Completed | 1 | 22 | US | Everolimus, RAD-001, Prednisone, Vincristine, PEG-Asparaginase, Oncaspar, Doxorubicin, Dexrazoxane, Zinecard | Dana-Farber Cancer Institute, Novartis | Acute Lymphoblastic Leukemia | 01/17 | 11/18 | | |
NCT01548807: Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy |
|
|
| Completed | 1 | 19 | US | Everolimus (RAD001) | Abramson Cancer Center of the University of Pennsylvania | Prostate Cancer Patients With Detectable PSA Following Prostatectomy | 01/17 | 01/17 | | |
NCT01184326: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer |
|
|
| Completed | 1 | 23 | US | pazopanib, Votrient, everolimus, RAD001 | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, GlaxoSmithKline, Novartis | Solid Tumor, Kidney Cancer | 03/17 | 03/17 | | |
NCT02063958: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors |
|
|
| Completed | 1 | 19 | US | SNX-5422 | Esanex Inc. | Cancer | 03/17 | 03/18 | | |
NCT01470209: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies |
|
|
| Completed | 1 | 43 | US | BKM120, Buparlisib, Everolimus, RAD001, Afinitor | Emory University, Novartis Pharmaceuticals | Solid Tumors, Lung Cancer | 05/17 | 05/17 | | |
NCT02454478: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) |
|
|
| Completed | 1 | 7 | Japan | Lenvatinib, Everolimus, Lenvatinib plus Everolimus orally once a day | Eisai Co., Ltd. | Carcinoma, Renal Cell | 05/17 | 05/17 | | |